Ischemia – modified albumin by albumin cobalt binding test: a false myth or reality
Scientific knowledge should be based on evidence. However, some scientific studies can be carried out without sufficient evidence. And these studies may mislead subsequent studies. Ischemia-modified albumin (IMA) is a relatively newly proposed biomarker. It is used not only for myocardial ischemia b...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2023-02-01
|
| Series: | Türk Biyokimya Dergisi |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/tjb-2022-0192 |
| _version_ | 1797848479088771072 |
|---|---|
| author | Yücel Doğan |
| author_facet | Yücel Doğan |
| author_sort | Yücel Doğan |
| collection | DOAJ |
| description | Scientific knowledge should be based on evidence. However, some scientific studies can be carried out without sufficient evidence. And these studies may mislead subsequent studies. Ischemia-modified albumin (IMA) is a relatively newly proposed biomarker. It is used not only for myocardial ischemia but also used for other pathological conditions in the body. IMA is commonly measured by albumin cobalt binding (ACB) assay. ACB is a simple colorimetric assay performed in patients’ sera. It is claimed that because of the ischemia or ischemia-reperfusion, the molecular structure of the N-terminus of human serum albumin is changed and therefore it cannot bind metal ions and cobalt ions added into the reaction mixture react with dithiothreitol to give a brown color. The clinical performance of the ACB assay is poor and it has not a strong correlation with other ischemia biomarkers. There are many analytical uncertainties in ACB assay and IMA as well. Despite the uncertainties, the ACB assay is still commonly used for many research studies. Therefore the theory of the ACB assay should be questioned. In this opinion paper, we discussed these uncertainties. In conclusion, there is insufficient evidence for the existence of IMA as a biomarker. The ACB assay essentially measures serum albumin concentration. There are many other interfering factors with the ACB assay. Therefore, the measurement of IMA in any pathological condition is a useless effort. |
| first_indexed | 2024-04-09T18:29:16Z |
| format | Article |
| id | doaj.art-f257c62964ef42eb8b1949e344a17c73 |
| institution | Directory Open Access Journal |
| issn | 1303-829X |
| language | English |
| last_indexed | 2024-04-09T18:29:16Z |
| publishDate | 2023-02-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Türk Biyokimya Dergisi |
| spelling | doaj.art-f257c62964ef42eb8b1949e344a17c732023-04-11T17:42:48ZengDe GruyterTürk Biyokimya Dergisi1303-829X2023-02-014811410.1515/tjb-2022-0192Ischemia – modified albumin by albumin cobalt binding test: a false myth or realityYücel Doğan0Department of Medical Biochemistry, Faculty of Medicine, Lokman Hekim University, Ankara, TürkiyeScientific knowledge should be based on evidence. However, some scientific studies can be carried out without sufficient evidence. And these studies may mislead subsequent studies. Ischemia-modified albumin (IMA) is a relatively newly proposed biomarker. It is used not only for myocardial ischemia but also used for other pathological conditions in the body. IMA is commonly measured by albumin cobalt binding (ACB) assay. ACB is a simple colorimetric assay performed in patients’ sera. It is claimed that because of the ischemia or ischemia-reperfusion, the molecular structure of the N-terminus of human serum albumin is changed and therefore it cannot bind metal ions and cobalt ions added into the reaction mixture react with dithiothreitol to give a brown color. The clinical performance of the ACB assay is poor and it has not a strong correlation with other ischemia biomarkers. There are many analytical uncertainties in ACB assay and IMA as well. Despite the uncertainties, the ACB assay is still commonly used for many research studies. Therefore the theory of the ACB assay should be questioned. In this opinion paper, we discussed these uncertainties. In conclusion, there is insufficient evidence for the existence of IMA as a biomarker. The ACB assay essentially measures serum albumin concentration. There are many other interfering factors with the ACB assay. Therefore, the measurement of IMA in any pathological condition is a useless effort.https://doi.org/10.1515/tjb-2022-0192analytical performancecardiac biomarkersclinical performanceevidence-based laboratory medicineischemia-modified albumin |
| spellingShingle | Yücel Doğan Ischemia – modified albumin by albumin cobalt binding test: a false myth or reality Türk Biyokimya Dergisi analytical performance cardiac biomarkers clinical performance evidence-based laboratory medicine ischemia-modified albumin |
| title | Ischemia – modified albumin by albumin cobalt binding test: a false myth or reality |
| title_full | Ischemia – modified albumin by albumin cobalt binding test: a false myth or reality |
| title_fullStr | Ischemia – modified albumin by albumin cobalt binding test: a false myth or reality |
| title_full_unstemmed | Ischemia – modified albumin by albumin cobalt binding test: a false myth or reality |
| title_short | Ischemia – modified albumin by albumin cobalt binding test: a false myth or reality |
| title_sort | ischemia modified albumin by albumin cobalt binding test a false myth or reality |
| topic | analytical performance cardiac biomarkers clinical performance evidence-based laboratory medicine ischemia-modified albumin |
| url | https://doi.org/10.1515/tjb-2022-0192 |
| work_keys_str_mv | AT yuceldogan ischemiamodifiedalbuminbyalbumincobaltbindingtestafalsemythorreality |